ResMed director Form 4 shows 1,331 options and 777-share sale

Rhea-AI Filing Summary

ResMed Inc. director Nicole Mowad-Nassar reported equity transactions involving the company’s stock. As a member of the board of directors, she filed a Form 4 as a single reporting person.

On 11/24/2025, she was granted stock options on 1,331 shares of ResMed common stock at an exercise price of $250.52 per share. These options become exercisable on the earlier of November 11, 2026, or the date of the first annual meeting of stockholders following the grant date. The filing also shows a disposition of 777 shares of ResMed common stock, reflecting routine personal trading activity by a director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mowad-Nassar Nicole

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock								777	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$250.52	11/24/2025		A		1,331		11/11/2026(1)	11/11/2032	ResMed Common Stock	1,331	$250.52	1,331	D

Explanation of Responses:

1. Represents the date on which options first become exercisable. The options vest on the earlier of (i) November 11, 2026, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date.

	Nicole Mowad-Nassar, director	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ResMed (RMD) disclose for director Nicole Mowad-Nassar?

The filing shows that director Nicole Mowad-Nassar reported both a grant of stock options and a disposition of 777 shares of ResMed common stock.

How many ResMed (RMD) stock options were granted to the director and at what price?

She received options on 1,331 shares of ResMed common stock with an exercise price of $250.52 per share.

When do Nicole Mowad-Nassar’s new ResMed (RMD) stock options vest?

The options vest on the earlier of November 11, 2026, or the date of the first annual meeting of stockholders following the grant date.

What type of filing is this for ResMed (RMD)?

This is a Form 4, which reports changes in beneficial ownership of ResMed securities by an insider, in this case a director.

Is Nicole Mowad-Nassar a 10% owner of ResMed (RMD)?

No. The filing indicates she is a director of ResMed Inc., and does not mark her as a 10% owner.

Does the ResMed (RMD) Form 4 indicate a single or joint reporting?

The Form 4 is marked as filed by one reporting person, reflecting only Nicole Mowad-Nassar’s transactions.